^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

Excerpt:
A proposed treatment algorithm for the management of hormone receptor (HR)-positive, HER2-negative MBC...Alpelisib/fulvestrant is a treatment option for patients with PIK3CA-mutant tumours (in exons 7, 9 or 20), prior exposure to an AI (± CDK4/6 inhibitors) and appropriate HbA1c levels...
Secondary therapy:
fulvestrant
DOI:
https://doi.org/10.1016/j.annonc.2021.09.019.
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Excerpt:
Treatment with alpelisib–fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer...kinase domains of PI3K (corresponding to exons 7, 9, and 20, respectively).
Secondary therapy:
fulvestrant
DOI:
10.1056/NEJMoa1813904
Trial ID: